| 查看: 907 | 回复: 6 | ||
| 当前主题已经存档。 | ||
[资源]
【分享】Tripose muse
|
||
|
Tripos Muse 1.0.1 | 154 MB Tripos International, a leading provider of drug discovery informatics products and services, today announced a collaboration agreement with AstraZeneca to develop a new drug discovery workflow solution. The centerpiece of the collaboration effort will be the development of Tripos' new Muse™ de novo design product, which is targeted for commercial release in the fourth quarter of 2008. Muse, which will be designed to accelerate the identification and optimization of lead candidates, will combine de novo design with multi-criteria optimization to deliver the first of many solutions being prepared for release on Tripos' highly flexible, adaptable and extensible Pantheon™ platform.Tripos' Muse Product Manager and Senior Scientist Brian Masek, Ph.D. added, "I'm excited about our collaboration with AstraZeneca and am optimistic that our versatile Pantheon platform will enable Muse to provide the powerful attributes we see emerging from this collaboration. The combination of Tripos' and AstraZeneca's technologies have already helped their drug discovery efforts and this collaboration will allow us to further those achievements and, importantly, to make this science available across the industry." Commenting on the agreement, James R. Empfield, Director of Lead Optimization Chemistry at AstraZeneca, said, "It's important to consider multiple parameters when defining the characteristics of a successful lead or drug candidate. For example, during the lead identification and optimization processes, factors including biological potency and selectivity and ADME properties must be considered. We look forward to enhancing these capabilities through our collaboration with Tripos." Jim Damewood, Principal Scientist II with AstraZeneca, added, "Merging AstraZeneca and Tripos capabilities in this area has the potential to provide a powerful and unique capability in ligand-based de novo design." It is anticipated that Muse will permit researchers to find structures, scaffolds, or side-chains that meet specific design objectives. Integration with other CAMD software will allow for multiple design criteria to be applied. Modelers will be able to quickly and easily generate ideas for new side chains that optimize a panel of biological and ADME properties, preserve key R-groups and invent new scaffolds. Tripos' General Manager, Patrick Flanagan, adds, "We are confident that the combination of technology and real world insight gained through our efforts with AstraZeneca will bring a unique product to our constituents. We believe that our collective efforts will offer discovery scientists the ability to leverage the robust modeling software of Tripos with the drug development expertise and experience of AstraZeneca to offer an easy to use software tool for candidate design." 下载地址 http://rapidshare.com/files/205123925/tropmgk.rar [ Last edited by zdhlover on 2009-11-24 at 13:05 ] |
回复此楼» 猜你喜欢
求调剂
已经有23人回复
-
301求调剂
已经有15人回复
-
304求调剂（085602，过四级，一志愿985）
已经有17人回复
-
302分求调剂 一志愿安徽大学085601
已经有12人回复
-
288环境专硕,求调材料方向
已经有23人回复
-
环境专硕调剂
已经有6人回复
-
22408 调剂材料
已经有6人回复
-
285求调剂
已经有12人回复
-
求调剂
已经有6人回复
-
085600材料与化工301分求调剂院校
已经有19人回复
2楼2009-03-10 20:13:32
3楼2009-03-10 21:24:35
4楼2009-03-10 23:55:02
5楼2009-03-13 08:58:59
6楼2009-03-13 14:41:31
7楼2009-03-24 11:15:13
